Theriva Biologics, Inc. (TOVX) Stock Analysis & Investment Frameworks
Theriva Biologics, Inc. (TOVX) stock analysis on Invetso. Review Theriva Biologics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Theriva Biologics, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Theriva Biologics, Inc. Key Financial Metrics
- Market Cap: $9.54M
- Revenue: $N/A
- ROE: -93.49%
- ROIC: -51.05%
- Dividend Yield: N/A
About Theriva Biologics, Inc.
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
Theriva Biologics, Inc. Investment Frameworks
Invetso analyzes Theriva Biologics, Inc. (TOVX) across the following frameworks:
- Theriva Biologics, Inc. 10Y Growth Potential
- Theriva Biologics, Inc. Scenario Analysis
- Theriva Biologics, Inc. Risks & Opportunities
- Theriva Biologics, Inc. Economic Moat
- Theriva Biologics, Inc. Business Model
- Theriva Biologics, Inc. Management
- Theriva Biologics, Inc. SWOT Analysis
- Theriva Biologics, Inc. Porter's 5 Forces
- Theriva Biologics, Inc. PESTLE Analysis
- Theriva Biologics, Inc. ESG Analysis